452 related articles for article (PubMed ID: 15548480)
1. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480
[TBL] [Abstract][Full Text] [Related]
2. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G
Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722
[TBL] [Abstract][Full Text] [Related]
3.
Cilia R; Laguna J; Cassani E; Cereda E; Pozzi NG; Isaias IU; Contin M; Barichella M; Pezzoli G
Neurology; 2017 Aug; 89(5):432-438. PubMed ID: 28679598
[TBL] [Abstract][Full Text] [Related]
4. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
[TBL] [Abstract][Full Text] [Related]
5. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
[TBL] [Abstract][Full Text] [Related]
6. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
8. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
[TBL] [Abstract][Full Text] [Related]
9. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
10. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
11. Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report.
Radder DLM; Tiel Groenestege AT; Boers I; Muilwijk EW; Bloem BR
J Parkinsons Dis; 2019; 9(2):437-439. PubMed ID: 30856121
[TBL] [Abstract][Full Text] [Related]
12. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Lieu CA; Kunselman AR; Manyam BV; Venkiteswaran K; Subramanian T
Parkinsonism Relat Disord; 2010 Aug; 16(7):458-65. PubMed ID: 20570206
[TBL] [Abstract][Full Text] [Related]
13. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
[TBL] [Abstract][Full Text] [Related]
14. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
Katzenschlager R; Manson AJ; Evans A; Watt H; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):295-7. PubMed ID: 14742609
[TBL] [Abstract][Full Text] [Related]
15.
Kamkaen N; Chittasupho C; Vorarat S; Tadtong S; Phrompittayarat W; Okonogi S; Kwankhao P
Molecules; 2022 May; 27(10):. PubMed ID: 35630617
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-Reduced
Johnson SL; Park HY; DaSilva NA; Vattem DA; Ma H; Seeram NP
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30131460
[No Abstract] [Full Text] [Related]
20. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
Ondo WG; Shinawi L; Moore S
Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]